Overview

A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.

Status:
Unknown status

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

To establish the anti-tumour effect of this metronomic combination regimen defined by progression-free survival (PFS) after two cycles of treatment (4 months) and 12 months of treatment, as well as response rate after any number of cycles of treatment ("best response"). To define the safety profile of the combination. To characterize pharmacodynamics of the drug combination with the use of angiogenic markers (CEP, CEC, microparticles).

Phase:

Phase 2

Details

Lead Sponsor:

Assistance Publique Hopitaux De Marseille

Treatments:

Celecoxib
Cyclophosphamide
Methotrexate
Vinblastine